Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC)
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Sacituzumab govitecan|DRUG: Eribulin|DRUG: Capecitabine|DRUG: Gemcitabine|DRUG: Vinorelbine
Sponsor: Gilead Sciences